PPD’s Evidera acquires RWE provider Medimix

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/metamoreworks)
(Image: Getty/metamoreworks)

Related tags: Ppd, Evidera, Real world evidence, RWE

PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.

President of Evidera​ Karen Kaucic, MD, said, “Through Medimix we will have rapid and efficient access to an extended and robust pool of global clinician and patient-level information to enhance client business decisions.”

This includes forecasting, marketing, commercial analytics, business intelligence, health economics, medical affairs, strategy, and licensing.

“It also will offer the opportunity to leverage data ownership in key therapeutic areas – oncology, for example – to gain enterprise experience and additional knowledge that can be applied across offerings and client engagements,”​ Kaucic explained.

Medimix’s proprietary cloud-based visualization and analytics interface “scans, extracts, and synthesizes big data and evidence-based information,” ​according to the company. It draws on a database of 2.2m health care providers with a focus on hematology and oncology.

The company’s primary solution, LiveTracker, monitors therapeutic markets and drugs in real time, providing RWE in more than 60 countries, including information about market structure, drug awareness and adoption levels, as well as patient profiles, treatment sequencing, and outcomes.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more